Youngchul Song
Boston Biomedical (United States)(US)Novartis (United States)(US)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Lung Cancer Treatments and Mutations, Cell Image Analysis Techniques, PI3K/AKT/mTOR signaling in cancer, Cancer Mechanisms and Therapy
Most-Cited Works
- → MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling(2007)4,440 cited
- → Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers(2008)1,324 cited
- → Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC(2010)1,055 cited
- → Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins(2008)522 cited
- → Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models(2012)378 cited
- → MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors(2012)358 cited
- → The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models(2016)321 cited
- → BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors(2011)277 cited
- → An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation(2010)261 cited
- → PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1(2013)217 cited